Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
|Articles|April 20, 2022
- April digital edition 2022
- Volume 14
- Issue 4
The ideal LASIK candidate
Author(s)Brooke Henson, Editor
Deciding whether or not a patient is a good fit for LASIK depends on many factors. Our experts agree your starting checklist should look something like this.
Advertisement
Articles in this issue
over 4 years ago
Case report: 16-year-old presents with asymptomatic glaucomaover 4 years ago
When pharmacies threaten treatment plans, look elsewhereover 4 years ago
Dry eye appears in an unlikely subjectover 4 years ago
How $420 co-op dollars netted $19,000 in revenueover 4 years ago
3 practice hacks for success with patientsover 4 years ago
Case report: the “other” AMDover 4 years ago
Adopting new technology without sacrificing practice spaceover 4 years ago
Contact lens disinfection methods still matterAdvertisement
Related to this article
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
FDA approves subcutaneous Enspryng for TED
3
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
4
FAQ: What clinicians should know as SYD-101 heads to FDA advisory committee
5